(lp0
S"Why Investors remained confident on Puma Biotechnology, Inc. , Tempur ... StockNewsJournal - 18 hours ago Investors who are keeping close eye on the stock of Puma Biotechnology, Inc.  established that the company was able to keep return on investment at -130.59 in the trailing twelve month while Reuters data showed that industry's average&nbsp;..."
p1
aS"Thursday's Biotech Insights: Aurinia Pharmaceuticals Inc , Puma ... Smarter Analyst - Mar 2, 2017 Puma Biotechnology Inc  shares lost one-quarter of their value today, after competitor Roche announced positive top-line results from the highly anticipated APHINITY trial, which explores usefulness of Perjeta in adjuvant breast cancer ...Puma Biotechnology Shares Plunge On Plans To Modify Neratinib European MAA ... - Benzinga"
p2
aS"Why Puma Biotechnology Inc. Got Hammered Today Motley Fool - Mar 2, 2017 The potential to establish a new standard of care where patients take Herceptin and Perjeta for a year could be problematic for Puma Biotechnology because its drug candidate, neratinib, was tested after just Herceptin use, the current standard of care.Puma Biotech shares plummet 26% after Roche reports positive results for late ... - MarketWatchHere's What Analysts Are Asking Puma Biotech Following Roche's Positive ... - Benzinga"
p3
aS'Why Puma Biotechnology Inc. Sold Lower Today Motley Fool - Oct 19, 2016 Puma Biotechnology is looking to raise $150 million selling shares, which will dilute current shareholders. Another $22.5 million of shares could also be sold within 30 days if the underwriters want the extra shares.Puma Biotechnology Inc  Swamped by New Shares - Scibility MediaPuma Biotechnology Announces Proposed Public Offering of Common Stock - Business Wire '
p4
aS"Why Puma Biotechnology Inc Roared Higher Today Motley Fool - Sep 20, 2016 Puma Biotechnology  was up as much as much as 15% today after announcing that the Food and Drug Administration accepted the company's marketing application for its breast cancer drug neratinib, although it's given up some of that gain&nbsp;...JP Morgan Comments on Puma Biotechnology Inc  Following NDA Acceptance - Smarter AnalystPuma Biotechnology Announces US FDA Acceptance of New Drug Application for ... - Business Wire "
p5
aS'Market Check: Narrowing in on Shares of Puma Biotechnology, Inc.  Baldwin Journal - 9 hours ago Puma Biotechnology, Inc.  currently has a 6 month price index of 0.57835. The six month price index is easily measured by dividing the current share price by the share price six months ago.'
p6
aS"Buy, Sell or Hold? Analysts Approach: Innoviva , Puma Biotechnology ? The USA Commerce - 18 hours ago Shares of Puma Biotechnology, Inc.  dropped -2.02% to $38.90. During the trading on 03/27/2017, Company's stock ranged from $39.70 to $38.15.Puma Biotechnology Inc  Broker Price Targets For The Coming Week - Fiscal StandardWatch List: Puma Biotechnology Inc  , Red Rock Resorts, Inc ... - NYSE Journal "
p7
aS"PUMA BIOTECHNOLOGY, INC.  Files An 8-K Changes in Registrant's ... Market Exclusive - Mar 24, 2017 Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer."
p8
aS'Puma Biotech Crashes After Bad News About Its Breast Cancer Drug Benzinga - Nov 14, 2016 Puma Biotechnology Inc  shares were down a whopping 21.73 percent on about 5 times its average volume. The plunge has come after a decent bump up last week since a recent low of $34.60 reached November 4.'
p9
aS'Puma Biotechnology Inc  Plunges 9.45% on March 21 Equities.com - Mar 21, 2017 Puma Biotechnology Inc  had a rough trading day for Tuesday March 21 as shares tumbled 9.45%, or a loss of $-4.2 per share, to close at $40.25.Option Market Alert: Puma Biotechnology Inc Implied Price Swing Hits An ... - CML News'
p10
a.